Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLodise, Thomas P.
dc.contributor.authorBassetti, Matteo
dc.contributor.authorFerrer Roca, Ricard
dc.contributor.authorNaas, Thierry
dc.contributor.authorNiki, Yoshihito
dc.contributor.authorPaterson, David L.
dc.contributor.authorZeitlinger, Markus
dc.contributor.authorEchols, Roger
dc.date.accessioned2022-09-09T12:53:33Z
dc.date.available2022-09-09T12:53:33Z
dc.date.issued2022-05
dc.identifier.citationLodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022 May;20(5):707–19.
dc.identifier.issn1744-8336
dc.identifier.urihttp://hdl.handle.net/11351/8120
dc.descriptionCarbapenem resistance; Gram-negative; Cefiderocol
dc.description.abstractIntroduction Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved antibiotics and older generic antibiotics with activity against CR Gram-negative bacteria were investigated in PF-RCTs in a variety of infections. Areas covered We searched Pubmed, Cochrane database and international clinical trial databases for PF-RCTs for the period between 2005 and 2020 and compared the study designs, patient populations, infection types, pathogens, and Day-28 all-cause mortality (ACM). Expert opinion PF-RCTs are particularly challenging to quantitatively assess and compare due to the heterogeneity in infection types, pathogens, CR mechanism, inclusion/exclusion criteria, and endpoints. Data interpretation is further complicated by lack of formal statistical analysis plans and/or non-inferiority design, and limited power across most PF-RCTs. The studies with new antibiotics (i.e. plazomicin, meropenem/vaborbactam, cefiderocol) ranked lower regarding feasibility, with relatively small sample sizes (analyzed: 37–118) versus the comparative effectiveness studies of older generic drugs (analyzed: 94–406). ACM ranged between 11.8% and 40% for CR Enterobacterales, 17.7% and 57.4% for CR Acinetobacter spp., and 20.0% and 30.8% for CR Pseudomonas aeruginosa. The information gathered must be considered carefully alongside the study limitations and caution should be exercised when making direct comparisons across trials.
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesExpert Review of Anti-infective Therapy;20(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMalalties bacterianes gramnegatives - Mortalitat
dc.subjectMedicaments antiinfecciosos
dc.subjectResistència als medicaments
dc.subject.meshGram-Negative Bacterial Infections
dc.subject.mesh/mortality
dc.subject.meshCarbapenems
dc.subject.meshDrug Resistance, Microbial
dc.titleAll-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/14787210.2022.2020099
dc.subject.decsinfecciones por bacterias gramnegativas
dc.subject.decs/mortalidad
dc.subject.decscarbapenems
dc.subject.decsfarmacorresistencia microbiana
dc.relation.publishversionhttps://doi.org/10.1080/14787210.2022.2020099
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lodise TP] Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA. [Bassetti M] Infectious Diseases Clinic, Department of Health Science, University of Genova and Policlinico San Martino IRCCS Hospital, Genova, Italy. [Ferrer R] Unitat de Cures Intensives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Naas T] Hôpital Bicetre, Bacteriology-Hygiene Unit, APHP-, University Paris-Saclay, Paris, France. [Niki Y] Division of Clinical Infectious Diseases, Showa University, Tokyo, Japan. [Paterson DL] UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia. [Zeitlinger M] Department of Clinical Pharmacology, Medical University, Vienna, Austria. [Echols R] Infectious Disease Drug Development Consulting, LLC, Easton, CT, USA
dc.identifier.pmid34937518
dc.identifier.wos000741842700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record